CD22-Targeted CAR T Cell Therapy for B Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for hematological malignancies, are inadequate, as evidenced by poor prognosis and high mortality rates, such as in non-Hodgkin's lymphoma and leukemia, highlighting the need for more effective therapies.
Innovation Solution
Development of a chimeric antigen receptor (CAR) comprising an antigen binding domain, a transmembrane domain, and an intracellular T cell signaling domain, specifically targeting CD22, which is expressed in 60-70% of B cell lymphomas and leukemias, allowing for targeted destruction of cancer cells while sparing early stages of B cell development and stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments (chemotherapy) are used, then cancer cells are treated, but prognosis remains poor and mortality rates are high
Solution Approach 1:
The treatment approach is segmented into multiple components: CAR transduction of T cells, targeted CD22 antigen recognition, and specific signaling domain activation. This segmentation allows precise targeting of cancer cells while sparing normal cells, improving prognosis and reducing mortality compared to non-specific chemotherapy.
Solution Approach 2:
The CAR T cell therapy applies local quality by directing immune activity specifically to CD22-expressing cancer cells. The antigen binding domain provides specificity for CD22, while the signaling domains (CD28, CD137, CD3ζ) provide localized activation only where the antigen is present, avoiding the harmful effects of systemic chemotherapy on healthy tissues.
2Productivity
If broad-spectrum chemotherapy is used, then cancer cells are killed, but normal cells including stem cells are also affected
Solution Approach 1:
The CAR structure is segmented into distinct functional domains: antigen binding domain for target recognition, transmembrane domain for structural support, and intracellular signaling domains for activation. This segmentation enables precise targeting of CD22+ cancer cells while leaving normal cells unaffected, eliminating the harmful effects of non-specific cell destruction.
Solution Approach 2:
The therapy applies local quality through CD22-specific antigen recognition, which is expressed in 60-70% of B cell lymphomas and leukemias but not in early B cell development or stem cells. This specificity allows cancer cell destruction without damaging normal tissues, reversing the harmful effects of broad-spectrum chemotherapy.
3Reliability
If CD22-targeted therapy is developed, then cancer specificity is improved, but binding affinity and specificity must be optimized
Solution Approach 1:
The patent optimizes binding affinity by selecting and modifying the antigen binding domain sequence (SEQ ID NOs: 1-6) to enhance CD22 recognition. The intracellular signaling domains (CD28, CD137, CD3ζ) are configured to provide appropriate activation thresholds, ensuring reliable cancer targeting while maintaining precision in binding characteristics.
Data Source
AI summary
The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.